Exploring Mesenchymal Stromal Cells as a Potential Therapy for Comorbid Osteoarthritis and Type 2 Diabetes Mellitus

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Background In recent years, the incidence rates of type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) have increased significantly. Currently developed therapeutic approaches (e.g., pharmacotherapy) exhibit limited efficacy in the treatment of T2DM and OA, failing to fully restore joint function and pancreatic islet function. Mesenchymal stem cells (MSCs) have demonstrated substantial potential in repairing cartilage damage, reducing blood glucose levels, and other related aspects. Objective This review aims to evaluate whether MSC therapy represents a potential therapeutic strategy for T2DM complicated with OA. Summary This review highlights the association between OA and T2DM and summarizes the applications of MSCs in the treatment of OA and T2DM, the potential mechanisms of MSCs, as well as relevant therapeutic strategies. Conclusion MSC therapy may exert therapeutic effects in models of T2DM complicated with OA. This approach is expected to serve as an innovative and effective therapeutic method, promoting research on stromal cells and their applications. However, further studies are still required to verify its safety and feasibility.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.